Podcasts

Articles

Webinars

Peer-Reviewed

Videos

American Cough Conference

Executives from Merck, Bellus Health, Bayer, and Shionogi highlighted their P2X3 data for chronic cough.

Companies Provide Trial Updates on P2X3 Blockers for Chronic Cough

OTC cough medicines may have some temporary benefit, but they don't penetrate the nerves in the airways, which are believed to be the mechanism behind refractory chronic cough, says Jacky Smith, MB, ChB, FRCP, PhD, professor of respiratory medicine at the University of Manchester and an honorary consultant at Manchester University NHS Foundation Trust.

OTC Drugs Don't Target Chronic Cough Mechanisms, Dr Jacky Smith Explains

Behavioral cough suppression therapy can be used to help patients with chronic cough manage their cough, prevent a cough, and even trigger their cough less often, explained Laurie Slovarp, PhD, CCC-SLP, associate professor in the School of Speech, Language, Hearing, and Occupational Sciences at University of Montana.

Dr Laurie Slovarp Outlines the Benefits of Behavioral Cough Suppression Therapy

Experts from around the world discussed how to best manage the clinical issues presented by patients with refractory chronic cough, who often spend years trying to find effective relief.

Improving Care for Patients With Refractory Chronic Cough

New antitussive trials are challenged by large placebo effects and the risk of the trial being unblinded due to adverse effects, explained Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.

The Large Placebo Effect in Cough Presents Major Challenges for Antitussive Trials

Updated guidelines for adults and children highlight confusion over the name of the condition and the need for greater evidence. 

Guideline Updates for Chronic Cough Kick Off American Cough Conference

The placebo effect is a major problem in cough trials and can make it impossible to tell the true pharmacological effect of the medicine being studied, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.

Dr Ron Eccles Discusses the Placebo Effect in Chronic Cough Clinical Trials

The P2X3 antagonists are the furthest along in the drug development process, but there are other potential drugs being evaluated to treat chronic cough, which currently has no FDA-approved therapies on the market, said Peter Dicpinigaitis, MD, chair of the American Cough Conference.

Dr Peter Dicpinigaitis Highlights Promising Therapies in the Pipeline for Chronic Cough

Desensitizing the cough reflex and new technologies based on artificial intelligence are some of the oral abstracts that Jacky Smith, MB, ChB, FRCP, PhD, professor of respiratory medicine at the University of Manchester and an honorary consultant at Manchester University NHS Foundation Trust, who chairs that session, is looking forward to at the American Cough Conference.



Dr Jacky Smith Discusses Key Research Abstracts  at the American Cough Conference

The 2-day meeting of the American Cough Conference will cover new developments in the treatment of cough, as well as insights into the mechanisms and management of cough, said Peter Dicpinigaitis, MD, chair of the American Cough Conference.